Low-dose, Nontitrated Dexmedetomidine Trials: Clarifying Possible Coenrollment
Michael C Reade
ANESTHESIOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Awarded by Pfizer (Melbourne, Australia)
Awarded by Pfizer
Prof. Reade reports receiving a single fee in 2009 to contribute to a Hospira (Melbourne, Australia) clinician advisory board preparing guidelines for the use of dexmedetomidine and a single fee plus travel expenses in 2016 to present the results of the Dexmedetomidine to Lessen ICU Agitation (DahLIA) trial (clinical trial no. NCT01151865) to an educational meeting funded by Pfizer (Melbourne, Australia). Pfizer has provided unrestricted sponsorship for both the DahLIA and Sedation Practice in Intensive Care Evaluation (SPICE) (clinical trial no. NCT01728558) trials, in which Prof. Reade is a chief investigator.